This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

September 20–23, 2021
Proudly part of Biotech Week BostonDelivered Digitally | US Eastern Daylight Time

Amy Nicole Nayar
VP US Patient Advocacy & Government Affairs at Novartis Gene Therapies


Working to leave a legacy of families whose lives are less burdened by disease Amy Nicole Nayar’s family witnessed a miracle when her brother gained access to an innovative treatment. Since then, she has dedicated her career to bringing that miracle to other families. Her early life experience moved her to pursue a Doctor of Pharmacy degree at the University of Michigan, where she first worked on gene therapy discovery in a lab. Inspired to encourage prescribers to consider holistic patient values, she pursued a Master of Science degree in health economics and outcomes research. Her first publication urged neurologists to treat towards improvements in patients quality of life. She went on to publish multiple manuscripts documenting the value of innovative treatment to all parts of the healthcare system. After serving in medical, commercial and public affairs roles at Pfizer, she created the worldwide patient advocacy function. She has since led patient advocacy and engagement teams at Porter Novelli, AbbVie, and Novartis Gene Therapies. Dr. Nayar has lived, and driven, the evolution of patient engagement and advocacy in the biotech industry over the past two decades. Known as a problem-solver, her goal is to collaborate with stakeholders to create solutions that lead to quantum leap improvements in research, policy, and care. She is honored to work with the rare disease community to harness the incredible opportunities we are now seeing come to life that disrupt patient care as we have known it.

Agenda Sessions

  • Partnering with patient advocacy groups

    On Demand